# Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

> **NCT00838383** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 29 (actual)

## Conditions studied

- Cardiac Surgery Subjects
- Subjects Undergoing CABG and/or Cardiac Valve Replacement

## Interventions

- **DRUG:** sitaxsentan (Thelin)
- **DRUG:** sitaxsentan (Thelin)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00838383
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-10
- **Primary completion:** 2008-03-31
- **Final completion:** 2008-03-31
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2022-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00838383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00838383, "Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00838383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*